7 terminated. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 7 |
| Phase 1 | 1 | Terminated 1 |
Follow Thyroid Cancer, Papillary: new trials by email Literature Review of Thyroid Cancer, Papillary trials Research Report on Thyroid Cancer, Papillary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral AMXT 1501 Dicaprate in Combination With IV DFMO AMXT1501, DFMO - Cancer, Solid Tumor | Phase 1 / Phase 2 | Terminated | Aminex Therapeutics, Inc. | 15 | 2022-11-29 | 2024-12-24 |
| Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors Tovorafenib - Melanoma, Solid Tumor | Phase 2 | Terminated | Day One Biopharmaceuticals, Inc. | 23 | 2021-07-15 | 2025-10-02 |
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Alectinib - Neoplasms, Colorectal Neoplasms | Phase 2 | Terminated | Hoffmann-La Roche | 1 | 2021-05-24 | 2023-08-07 |
| Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial Durvalumab, Tremelimumab - Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma | Phase 2 | Terminated | Grupo Espanol de Tumores Neuroendocrinos | 79 | 2019-04-02 | 2026-03-11 |
| Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer Lenvatinib - Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma | Phase 2 | Terminated | Emory University | 4 | 2019-01-16 | 2022-11-10 |
| Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer Lenvatinib, Sorafenib, Cabozantinib - Thyroid Cancer, Thyroid Cancer, Medullary | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 6 | 2018-08-06 | 2021-07-14 |
| Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer sorafenib tosylate, laboratory biomarker analysis, pharmacological study - Anaplastic Thyroid Cancer, Insular Thyroid Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 25 | 2004-10-01 | 2014-01-16 |
Adenocarcinoma, Follicular (4) · Thyroid Neoplasms (4) · Colorectal Neoplasms (3) · Melanoma (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Head and Neck Neoplasms (2) · Neoplasms (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Astrocytoma (1) · Brain Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1)
Adenocarcinoma (7) · Adenocarcinoma, Papillary (7) · Carcinoma (7) · Endocrine Gland Neoplasms (7) · Endocrine System Diseases (7) · Neoplasms by Histologic Type (7) · Neoplasms, Glandular and Epithelial (7) · Neoplasms by Site (6) · Thyroid Diseases (6) · Head and Neck Neoplasms (5) · Neoplasms (5) · Neoplasms, Germ Cell and Embryonal (4) · Neoplasms, Nerve Tissue (4) · Neuroectodermal Tumors (4) · Female Urogenital Diseases (3)
Sorafenib (2) · lenvatinib (2) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · Fluorodeoxyglucose F18 (1) · Magnetic Resonance Spectroscopy (1) · alectinib (1) · cabozantinib (1) · durvalumab (1) · tovorafenib (1) · tremelimumab (1) · vandetanib (1)
Aminex Therapeutics, Inc. (1) · Day One Biopharmaceuticals, Inc. (1) · Emory University (1) · Grupo Espanol de Tumores Neuroendocrinos (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Hoffmann-La Roche (1) · National Cancer Institute (NCI) (1)
United States (6) · Australia (2) · Spain (2) · Belgium (1) · Canada (1) · France (1) · South Korea (1)
Christine H. Chung, M.D. (1) · Jaume Capdevila, M.D., Ph.D. (1) · Manisha Shah (1) · Michael Armstrong, MD (1) · Sue Lee, MD (1) · Taofeek K. Owonikoko, MD, PhD (1)
2018 (1), N01CM62206 (1), N01CM62207 (1), P30CA016058 (1), U01CA076576 (1)